State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China.
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1382-1391. doi: 10.1016/j.ijrobp.2018.01.117. Epub 2018 Mar 30.
To estimate the clinical benefit and cost-effectiveness of routine head and neck magnetic resonance imaging (MRI) in the follow-up of patients with nasopharyngeal carcinoma after definitive intensity modulated radiation therapy.
Two Markov models were developed to compare the cost and effectiveness of 3 strategies: routine clinical surveillance without serial imaging and routine annual and biannual MRI surveillance in the first 5 years. Two hypothetical cohorts of patients with primary stage T1-2 or T3-4 nasopharyngeal carcinoma who achieved complete remission after radical treatment and remained asymptomatic were analyzed. Baseline probabilities, transition probabilities, utilities, and costs were derived from published studies. Markov models were used to calculate life-time costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Model robustness was addressed via univariable and probabilistic sensitivity analyses.
In T1-2 patients, surveillance strategies utilizing routine MRI provided few QALYs compared with non-MRI clinical follow-up (annual MRI, 0.022 QALYs; biannual MRI, 0.035 QALYs), whereas the costs associated with MRI surveillance were considerable. Compared with clinical follow-up, the ICERs for annual and biannual MRI strategies were $328,389 and $403,857 per QALY. In T3-4 patients, annual and biannual MRI surveillance provided 0.052 and 0.088 incremental QALYs, with ICERs of $156,204 and $169,772 per QALY, respectively. Model conclusions were robust and remained stable in 1-way and probabilistic sensitivity analyses.
Routine MRI surveillance was not cost-effective owing to the high cost of MRI coupled with low rates of failure in T1-2 patients, whereas annual MRI surveillance was the dominant and possibly a cost-effective strategy for T3-4 patients, depending on the social willingness to pay.
评估常规头颈部磁共振成像(MRI)在调强放疗后鼻咽癌患者随访中的临床获益和成本效益。
建立了两个马尔可夫模型,以比较 3 种策略的成本和效果:不进行连续影像学检查的常规临床监测,以及在最初 5 年内每年和每两年进行常规 MRI 监测。分析了两个假设的队列,分别为完全缓解后根治性治疗且无症状的原发性 T1-2 或 T3-4 期鼻咽癌患者。基础概率、转移概率、效用和成本来自已发表的研究。马尔可夫模型用于计算终生成本、质量调整生命年(QALY)和增量成本效益比(ICER)。通过单变量和概率敏感性分析解决模型稳健性问题。
在 T1-2 患者中,与非 MRI 临床随访相比,常规 MRI 监测策略提供的 QALYs 很少(每年 MRI 监测为 0.022 QALY,每两年 MRI 监测为 0.035 QALY),而 MRI 监测的相关成本却很高。与临床随访相比,每年和每两年进行 MRI 监测的 ICER 分别为每 QALY 328389 美元和 403857 美元。在 T3-4 患者中,每年和每两年的 MRI 监测分别提供 0.052 和 0.088 个增量 QALY,ICER 分别为每 QALY 156204 美元和 169772 美元。模型结论是稳健的,并且在单因素和概率敏感性分析中保持稳定。
由于 MRI 成本高,T1-2 患者的失败率低,常规 MRI 监测不具有成本效益,而每年进行 MRI 监测对于 T3-4 患者是主导且可能具有成本效益的策略,具体取决于社会对支付意愿。